

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/502,307
Filing Date	July 22, 2004
First Named Inventor	Roberto Burioni
Art Unit	1648
Examiner Name	Zachariah Lucas
Attorney Docket Number	937-PCT-US

Sheet 1 of 1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	DIETZSCHOLD et al., "Delineation of putative mechanisms involved in antibody-mediated clearance of rabies virus from the central nervous system", Proc. Natl. Acad. Sci., USA, Vol 89, Pages 7252-7256 (1992).	
	2	FUJINAMI et al., "Survival of Athymic (nu/nu) Mice after Theiler's Murine Encephalomyelitis Virus Infection by Passive Administration of Neutralizing Monoclonal Antibody", Journal of Virology, Vol. 63, No. 5, Pages 2081-2087 (1989).	
	3	LAVILLETTE et al., "Human Serum Facilitates Hepatitis C Virus Infection, and Neutralizing Responses Inversely Correlate with Viral Replication Kinetics at the Acute Phase of Hepatitis C Virus Infection", Journal of Virology, Vol. 79, No. 10, Pages 6023-6034 (2004).	
	4	LAW et al., "Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge", Nature Publishing Group, Pages 1-3 (2007).	
	5	LOGVINOFF et al., "Neutralizing antibody response during acute and chronic hepatitis C virus infection", PNAS, Vol. 101, No. 27, Pages 10149-10154 (2004).	
	6	MOORE et al., "HIV-1 neutralizing antibodies: How full is the bottle", Nature America Inc, Vol. 5, No. 2, Pages 142-144, (1999).	
	7	VIRGIN et al., "Antibody Protects against Lethal Infection with the Neurally Spreading Reovirus Type 3 (Dearing)", Journal of Virology, Vol. 62, No. 12, Pages 4594-4604 (1988).	
	8	WOHLFART, Claes, "Neutralization of Adenoviruses: Kinetics, Stoichiometry, and Mechanisms", Journal of Virology, Vol. 62, No. 7, Pages 2321-2328 (1988).	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.